NOXXON TO ATTEND THE GERMAN FALL CONFERENCE ON SEPTEMBER 6 & 7,
2021
Berlin, Germany, August 25, 2021, 08:00 a.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX),
a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it will participate in the German Fall conference taking place from September 6 to September 7, 2021. The capital market conference for small and mid-cap companies organized by Equity Forum will take place in the form of virtual one-on-one meetings.
The conference aims at bringing together public company representatives across sectors with investors, analysts, financial journalists, intermediaries and financial industry experts. Around 100 companies will participate in this year's summit to present their equity story. NOXXON's CEO, Aram Mangasarian, will be available for meetings on both conference days. To schedule a meeting please contact the conference organizer or send an email to noxxon@noxxon.com.
For more information, please contact:
NOXXON Pharma N.V. Aram Mangasarian, Ph.D. Chief Executive Officer Tel. +49 (0) 30 726247 0 amangasarian@noxxon.com
Investor and Media Relations:
LifeSci Advisors
Guillaume van Renterghem Tel. +41 (0) 76 735 01 31 gvanrenterghem@lifesciadvisors.com
NewCap Arthur Rouillé
Tel. +33 (0) 1 44 71 00 15 arouille@newcap.fr
About NOXXON
NOXXON's oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON's approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON's lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second- line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has
delivered interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company's second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. Further information can be found at: www.noxxon.com.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp
Visit NOXXON on LinkedInand Twitter
About the GLORIA Study
GLORIA (NCT04121455) is NOXXON's dose-escalation, phase 1/2 study of NOX-A12 in combination with irradiation in first-line glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).
About the OPTIMUS Study
OPTIMUS (NCT04901741) is NOXXON's open-labeltwo-arm phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.
Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.
Attachments
- Original document
- Permalink
Disclaimer
Noxxon Pharma NV published this content on 25 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2021 05:43:02 UTC.